8-K: Reviva Pharmaceuticals Establishes $50 Million At-the-Market Equity Offering Program

Reviva Pharmaceuticals Holdings, Inc. has entered into an At Market Issuance Sales Agreement with B. Riley Securities and Alliance Global Partners to potentially sell up to $50 million of its common stock.

Summary

• Reviva Pharmaceuticals Holdings, Inc. (RVPH) has established an At Market Issuance Sales Agreement (ATM) with B. Riley Securities, Inc. and Alliance Global Partners.
• This agreement allows the Company to offer and sell, from time to time, shares of its common stock with an aggregate offering price of up to $50 million.
• Sales will be conducted through the Agents as an at-the-market offering on The Nasdaq Capital Market or any other existing trading market for the Common Stock.
• The Company will pay the Agents a commission equal to three percent (3%) of the gross sales proceeds of any shares sold through the Agents under the Agreement.
• The offering is registered under the Company's shelf Registration Statement on Form S-3 (File No. 333-276848), which was declared effective on February 13, 2024.
• A prospectus supplement specifically relating to this offering is to be filed with the SEC on May 30, 2025.

Sentiment

Score: 6

Explanation: The establishment of an ATM program is generally a positive step for a company needing flexible access to capital, indicating proactive financial management. However, it also signals potential future dilution for existing shareholders, which can be viewed negatively. The score reflects a slightly positive outlook due to enhanced financial flexibility, balanced by the inherent dilutive nature of equity raises.

Positives

• Provides Reviva Pharmaceuticals with a flexible and efficient mechanism to raise capital as needed.
• Allows the company to access public markets for financing without a traditional underwritten offering, potentially reducing costs and time.
• The 'at-the-market' nature allows for sales to be made opportunistically based on prevailing market conditions and the company's capital requirements.

Negatives

• Potential for dilution of existing shareholders as new common stock shares are issued and sold under the program.
• The actual amount and timing of capital raised are uncertain, as sales depend on market conditions and the agents' 'commercially reasonable efforts,' with no guarantee of specific sales volumes.
• The 3% commission paid to agents will reduce the net proceeds received by the company from sales.

Risks

• Unfavorable market conditions may limit the company's ability to sell shares or raise the full $50 million under the program.
• Significant sales of common stock under the ATM program could put downward pressure on the company's stock price due to increased supply.
• The company bears sole responsibility for ensuring compliance with offering limitations, including the maximum amount registered and the number of authorized but unissued shares.

Future Outlook

The agreement provides Reviva Pharmaceuticals with the ability to raise capital opportunistically in the future, up to an aggregate of $50 million, depending on market conditions and the company's funding needs. No specific timeline or amount for future sales is provided, as sales will be made at the company's sole discretion.

Management Comments

• The Company confirms its agreement (this Agreement) with B. Riley Securities, Inc. (B Riley) and Alliance Global Partners (AGP) (each of B Riley and AGP, an Agent, and collectively, the Agents) as follows.
• The Company acknowledges and agrees that there can be no assurance that the Designated Agent will be successful in selling Placement Shares, and the Designated Agent will incur no liability or obligation to the Company if it does not sell Placement Shares for any reason other than a failure to use commercially reasonable efforts.

Industry Context

At-the-market (ATM) offering programs are a common financing tool for publicly traded companies, particularly in sectors like biotechnology, allowing them to raise capital flexibly over time without the immediate price impact of a large, fixed-price offering. This mechanism is often favored by companies that anticipate ongoing capital needs for research and development or operational expenses, providing continuous access to equity markets.

Comparison to Industry Standards

• The 3% commission rate for the agents is within the typical range for ATM offerings, which generally fall between 1% and 3.5% of gross proceeds, making it a standard cost for this type of financing.
• The use of an ATM facility is a common practice among small to mid-cap biotechnology companies, such as those developing novel drug candidates, to fund research and development, clinical trials, and general corporate purposes, similar to how companies like Xencor (XNCR) or Geron (GERN) have utilized such programs for ongoing funding.
• The maximum offering size of $50 million is a moderate amount for a biotech company at this stage, indicating a strategic approach to manage potential dilution while securing sufficient capital for near-term operations or specific development milestones.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholders due to the issuance of new common stock.
• Company (Management/Operations): Enhanced financial flexibility to fund operations, research and development, and other corporate purposes.
• Agents (B. Riley, Alliance Global Partners): Will earn commissions (3% of gross sales proceeds) for facilitating the sales.

Next Steps

• The Company may, from time to time, issue and sell shares of its common stock through the agents under the established ATM program.
• The agents will use commercially reasonable efforts to sell shares based on instructions from the Company.
• The Company will file a prospectus supplement on May 30, 2025, related to the offering.

Key Dates

Keywords

Reviva Pharmaceuticals, RVPH, At-the-Market Offering, ATM, Equity Offering, Capital Raise, Common Stock, SEC Filing, Form 8-K, B. Riley Securities, Alliance Global Partners, Nasdaq Capital Market, Dilution